CLOs on the Move

Teligent

www.teligent.com

 
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Called TICO, our strategy is focused on developing and selling pharmaceutical products in the Topical, Injectable, Complex and Ophthalmic markets. Based in Buena, New Jersey, we have approximately 200 employees working at our 33,000 square-foot manufacturing and R&D complex, as well as in our Canada and Estonia operations. We are currently expanding our New Jersey site to include a sterile injectable, isolator-based manufacturing suite and an expanded footprint for the production of our topical products. There are three ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Philip Yachmetz
 Chief Legal Officer and Corporate Secretary Profile
Martin Wilson
 General Counsel Profile
Martin Wilson
 General Counsel Profile

Similar Companies

HearingLife

HearingLife offers hearing wellness care and hearing aids for people who want to achieve optimal results. For a free hearing assessment call (844) 836-5003.

Balboa United

Pharmasset

Pharmasset, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Brunk Industries

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.